Systemic pharmacokinetics and cellular pharmacology of zidovudine in human immunodeficiency virus type 1-infected women and newborn infants

被引：53

作者：

Rodman, JH

Flynn, PM

Robbins, B

Jimenez, E

Bardeguez, AD

Rodriguez, JF

Blanchard, S

Fridland, A

机构：

[1] Univ Tennessee, St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA

[2] Univ Tennessee, St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA

[3] Univ Tennessee, Dept Clin Pharm, Memphis, TN 38105 USA

[4] Univ Tennessee, Dept Pediat, Memphis, TN 38105 USA

[5] Univ Puerto Rico, San Juan City Hosp, Dept Pediat, San Juan, PR 00936 USA

[6] Univ Puerto Rico, Sch Med, San Juan, PR 00936 USA

[7] Univ Med & Dent New Jersey, Newark, NJ 07103 USA

来源：

JOURNAL OF INFECTIOUS DISEASES | 1999年 / 180卷 / 06期

关键词：

D O I：

10.1086/315152

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Systemic and intracellular pharmacokinetics of zidovudine were determined for 28 human immunodeficiency virus type 1-infected pregnant women and their newborn infants. Plasma zidovudine and intracellular zidovudine monophosphate and triphosphate concentrations were determined in serial maternal samples and cord blood at delivery. Higher levels of cord blood zidovudine were associated with lower maternal zidovudine clearance and longer infusion times, Median levels of zidovudine monophosphate and triphosphate in maternal(1556 and 67 fmol/10(6) cells) and cord (1464 and 70 fmol/10(6) cells) blood were similar but highly variable. Intersubject pharmacokinetic variability for zidovudine is substantial, but intravenous therapy provides plasma concentrations and intracellular zidovudine triphosphate levels consistent with high antiviral activity, The substantial amount of intracellular zidovudine triphosphate in cord blood provides an explanation for the clinical success of zidovudine in reducing vertical transmission. Studies of simpler oral regimens of zidovudine can now be evaluated regarding the ability to achieve these pharmacologic end points associated with highly effective parenteral therapy.

引用

页码：1844 / 1850

页数：7

共 16 条

[1] The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1 -: A meta-analysis of 15 prospective cohort studies [J].

Andiman, W ;

Boucher, M ;

Burns, D ;

Bryson, Y ;

Farley, J ;

Fowler, H ;

Gabiano, C ;

Galli, L ;

Hutto, C ;

Kind, C ;

Korber, B ;

Kovacs, A ;

Krogstad, P ;

Landesman, S ;

Lapointe, N ;

Lemay, M ;

Lew, J ;

Mandelbrot, L ;

Mayaux, MJ ;

Mellins, R ;

Minkoff, H ;

Mofenson, L ;

Nielsen, K ;

Newell, ML ;

Pardi, G ;

Peavy, H ;

Peckham, C ;

Read, J ;

Rother, C ;

Rudin, C ;

Scott, G ;

Semprini, A ;

Shearer, W ;

Simonds, R ;

Simpson, B ;

Stek, A ;

Tovo, PA ;

Tuomala, R ;

Van Dyke, R ;

Weedon, J ;

de Martino, M ;

Lindsay, M ;

Belair, S ;

Chan, L ;

Harris, D ;

Kalish, L ;

Muenz, L ;

Nugent, R ;

Schluchter, M ;

Durako, S .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (13) :977-987

[2] ZIDOVUDINE PHOSPHORYLATION IN HIV-INFECTED PATIENTS AND SERONEGATIVE VOLUNTEERS [J].

BARRY, M ;

WILD, M ;

VEAL, G ;

BACK, D ;

BRECKENRIDGE, A ;

FOX, R ;

BEECHING, N ;

NYE, F ;

CAREY, P ;

TIMMINS, D .

AIDS, 1994, 8 (08) :F1-F5

[3] REDUCTION OF MATERNAL-INFANT TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 WITH ZIDOVUDINE TREATMENT [J].

CONNOR, EM ;

SPERLING, RS ;

GELBER, R ;

KISELEV, P ;

SCOTT, G ;

OSULLIVAN, MJ ;

VANDYKE, R ;

BEY, M ;

SHEARER, W ;

JACOBSON, RL ;

JIMENEZ, E ;

ONEILL, E ;

BAZIN, B ;

DELFRAISSY, JF ;

CULNANE, M ;

COOMBS, R ;

ELKINS, M ;

MOYE, J ;

STRATTON, P ;

BALSLEY, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (18) :1173-1180

[4]

D'Argenio DZ, 1997, ADAPT 2 USERS GUIDE

[5] Concentration-controlled zidovudine therapy [J].

Fletcher, CV ;

Acosta, EP ;

Henry, K ;

Page, LM ;

Gross, CR ;

Kawle, SP ;

Remmel, RP ;

Erice, A ;

Balfour, HH .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (03) :331-338

[6] PHOSPHORYLATION OF 3'-AZIDO-3'-DEOXYTHYMIDINE AND SELECTIVE INTERACTION OF THE 5'-TRIPHOSPHATE WITH HUMAN-IMMUNODEFICIENCY-VIRUS REVERSE-TRANSCRIPTASE [J].

FURMAN, PA ;

FYFE, JA ;

STCLAIR, MH ;

WEINHOLD, K ;

RIDEOUT, JL ;

FREEMAN, GA ;

LEHRMAN, SN ;

BOLOGNESI, DP ;

BRODER, S ;

MITSUYA, H ;

BARRY, DW .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (21) :8333-8337

[7]

GAO WY, 1994, J BIOL CHEM, V269, P12633

[8]

LACEY SF, 1992, J BIOL CHEM, V267, P15789

[9] THE PHARMACOKINETICS AND SAFETY OF ZIDOVUDINE IN THE 3RD TRIMESTER OF PREGNANCY FOR WOMEN INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS AND THEIR INFANTS - PHASE-I ACQUIRED-IMMUNODEFICIENCY-SYNDROME CLINICAL-TRIALS GROUP-STUDY (PROTOCOL 082) [J].

OSULLIVAN, MJ ;

BOYER, PJJ ;

SCOTT, GB ;

PARKS, WP ;

WELLER, S ;

BLUM, MR ;

BALSLEY, J ;

BRYSON, YJ ;

BOND, B ;

EFANTISPOTTER, J ;

GILLESPIE, S ;

GOURLEY, J ;

HELFGOTT, A ;

LAI, S ;

MITCHELL, C ;

OROURKE, S ;

PARKS, W ;

PERRYMARX, D ;

SCOTT, W ;

SETTLAGE, R ;

STIEHM, R .

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1993, 168 (05) :1510-1516

[10] Zidovudine phosphorylation after short-term and long-term therapy with zidovudine in patients infected with the human immunodeficiency virus [J].

Peter, K ;

Gambertoglio, JG .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (02) :168-176

← 1 2 →